Literature DB >> 15280660

Molecular functions of BRCA1 in the DNA damage response.

Ralph Scully1, Anyong Xie, Ganesh Nagaraju.   

Abstract

Ten years ago, a concerted effort from several labs resulted in the cloning of BRCA1, the first of two major hereditary breast/ovarian cancer predisposition genes. Since that time, BRCA1 has been linked to several key nuclear functions connected with the prevention of genomic instability. In particular, BRCA1 functions in concert with Rad51, BRCA2 and other genes to control double strand break repair (DSBR) and homologous recombination. Here, we reassess the role of BRCA1 and its associated proteins in this process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280660     DOI: 10.4161/cbt.3.6.842

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  18 in total

Review 1.  Functional assays for BRCA1 and BRCA2.

Authors:  Marcelo A Carvalho; Fergus J Couch; Alvaro N A Monteiro
Journal:  Int J Biochem Cell Biol       Date:  2006-08-18       Impact factor: 5.085

2.  TopBP1 contains a transcriptional activation domain suppressed by two adjacent BRCT domains.

Authors:  Roni H G Wright; Edward S Dornan; Mary M Donaldson; Iain M Morgan
Journal:  Biochem J       Date:  2006-12-15       Impact factor: 3.857

Review 3.  Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Nat Rev Mol Cell Biol       Date:  2013-09       Impact factor: 94.444

4.  Characterization of LGALS3 (galectin-3) as a player in DNA damage response.

Authors:  Renato S Carvalho; Vanessa C Fernandes; Thales C Nepomuceno; Deivid C Rodrigues; Nicholas T Woods; Guilherme Suarez-Kurtz; Roger Chammas; Alvaro N Monteiro; Marcelo A Carvalho
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

Review 5.  Genomic instability in breast cancer: pathogenesis and clinical implications.

Authors:  Kevin A Kwei; Yvonne Kung; Keyan Salari; Ilona N Holcomb; Jonathan R Pollack
Journal:  Mol Oncol       Date:  2010-04-09       Impact factor: 6.603

Review 6.  Parameters for individualizing systemic therapy in non-small cell lung cancer.

Authors:  Shirish M Gadgeel; Michele L Cote; Ann G Schwartz; Larry H Matherly; Antoinette Wozniak; Gerold Bepler
Journal:  Drug Resist Updat       Date:  2010-11-03       Impact factor: 18.500

Review 7.  Structural biology of poly(A) site definition.

Authors:  Qin Yang; Sylvie Doublié
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-04-27       Impact factor: 9.957

Review 8.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

9.  BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.

Authors:  Katherine V Clark-Knowles; Anna M O'Brien; Johanne I Weberpals
Journal:  J Oncol       Date:  2010-02-22       Impact factor: 4.375

10.  BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.

Authors:  Yongxian Ma; Saijun Fan; Changyan Hu; Qinghui Meng; Suzanne A Fuqua; Richard G Pestell; York A Tomita; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2009-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.